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Abstract
In the past decade, progress has been made in the development of targeted therapies for advanced
renal cell carcinoma. However, as multiple therapeutic choices become available for clinicians, we
currently lack effective indicators to allow physicians to choose the best treatment option for
specific patients. For approved targeted therapies, potential molecules that could indicate drug
effectiveness in a specific tumor follow naturally from both the therapeutic mechanism and the
previously elucidated tumor biology. However, in advanced RCC, the use of these molecules as
biomarkers for treatment selection has shown equivocal results and requires further investigation.
In addition to looking at specific molecular targets, subclassification of tumors based on their
molecular characteristics may also allow stratification of patients based on therapeutic benefits,
providing information for treatment selection. Furthermore, the continued development of such
tumor classification schemes will hopefully uncover other molecular targets that warrant
development as future RCC therapies. The use of molecular classification of patients’ tumors for
treatment selection will provide the opportunity to increase the effectiveness of currently available
therapies for advanced RCC and to judiciously pursue promising options for future RCC therapies.
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Introduction
With the advent of targeted therapy for various cancer types, the importance of
understanding the underlying molecular pathogenesis of tumors escalated, as identifying the
specific molecular pathways altered in an individual patient’s tumor allow for more effective
treatment selection for patients. Many notable successes for such classification schemes
enhancing predictions for tumor response to specific therapy are recognized in acute
leukemias, breast cancer, and non-small-cell lung cancer. In acute leukemia, DNA
microarray data discovered molecular distinctions which allowed for the a priori
stratification of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL),
which opened the door for predicting cancer subtype classification and suggested the genetic
heterogeneity of cancer types1. In the case of breast cancer, tumors which express HER2
have been shown to be uniquely sensitive to targeting with a neutralizing therapeutic
antibody, traztuzumab2. In non-small-cell lung cancer, mutations in the epidermal growth
factor receptor (EGFR) confer sensitivity to treatment with EGFR small molecular tyrosine
kinase inhibitors, erlotinib and gefitinib3–5. With these impressive success stories, the
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exploration of targeted therapies for cancer treatment has exploded and, due to its prominent
resistance to traditional chemotherapeutic agents, renal cell carcinoma (RCC) is a prime
candidate for targeted therapy.
In the United States, the incidence of RCC is currently rising, with it being the 7th leading
cause of cancer in men and the 8th in women6. Despite the high incidence of RCC, median
life expectancy remains 10 to 26 months, depending on other clinical factors. Renal cell
carcinomas are separated into three main histological subtypes, including clear cell,
papillary, and chromophobe. These histological subtypes are very diverse diseases and,
when analyzed with molecular techniques, they actually tend to segregate into groups with
distinct molecular characteristics, most likely due to subtype-specific activation of molecular
pathways which also contribute the histological appearance observed in those tumor cells.
Discovering these underlying molecular pathways and others which are differentially
activated within histological subtypes will allow for more thorough exploration of targeted
therapies for RCC and promises to improve the effectiveness of targeted therapies through
stratification of which tumors will respond. In this review, we will focus on the currently
available therapy for RCC, potential biomarkers and molecular classification of these
therapies, development of molecular classification schemes to direct future personalized
therapeutic strategies, and examination of the importance of exploring genome wide changes
in RCC to further elucidate key molecular pathways and future drug development.
Current Therapy for Renal Cell Carcinoma
As suggested in the above introduction, advanced renal cell carcinoma is typically resistant
to chemotherapy and currently available treatment options are limited in terms of their
efficacy and response rates. While our understanding of the genetic pathways involved in
the pathogenesis of RCC has vastly expanded in the past decades, available treatment
strategies do not target molecules directly involved in these pathways. Instead, current
therapies act by either broadly activating the immune system or inhibiting molecules located
far downstream of the actual molecular insult.
Cytokine therapy
For metastatic renal cell carcinoma, immunotherapy options include high dose IL-2 and
interferon. High dose IL-2 acts through the activation of cytotoxic T cells and growth of T
helper cells, while interferon enhances MHC expression and antigen presentation. The use
of high dose IL-2 remains an integral part of renal carcinoma therapy because of the small
percentage who achieve complete responses and durable remissions with this therapy.
However, this treatment is controversial due to the significant toxicities associated with its
use, which include hypotension, thrombocytopenia, dyspnea, nephrotoxicity, and
disorientation7. As a result of the significant toxicity profile of high dose IL-2, various
strategies of low dose IL-2 and/or Interferon-alfa have been explored due to the decreased
toxicity profile of these immunotherapy agents and potential to mimic the high dose IL-2 T
cell stimulatory effects. These lower intensity therapies, however, compromise patient
activity as in one comparative study in which high dose IL-2 displayed higher complete and
overall response rates (8%, 25%) than a combined low dose therapy (2%, 12%)7. Similarly,
a direct comparison of high and low dose IL-2 demonstrated response rates of 21% and 13%
respectively8. Clearly the ability to achieve optimal drug exposure is important for attaining
this responses; however, if tumor or host characteristics were available to reliably identify
the subset of patients who have the greatest potential to tremendously benefit from these
therapies on the basis of the underlying biology of their tumors, the enthusiasm for cytokine
therapy would regain momentum. Such indicators have long been sought, and continue to be
actively investigated. Due to the inconsistent response rates based on clinical criteria and
substantial toxicities associated with IL-2, targeted therapies such as anti-VEGF pathway
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and mTOR inhibitory agents have become the mainstays of treatment options for advanced
RCC9.
VEGF pathway directed therapy
In clear cell renal cell carcinoma, as many as 90% of cases contain mutations located in the
von Hippel-Lindau tumor suppressor gene, which results in the stabilization of hypoxia
inducible factors (HIF-1α and HIF-2α), a family of transcription factors that promote
increased expression of hypoxia-inducible genes, including vascular endothelial growth
factor (VEGF)9. Vascular endothelial growth factor activates tumor angiogenesis, while
inhibiting dendritic cell maturation and tumor cell apoptosis9, making it an attractive target
for treatment of renal cell carcinoma, which produces abundant VEGF and is
characteristically a vascular tumor. VEGF-targeted therapeutic options include VEGF
neutralizing antibody and VEGF receptor tyrosine kinase inhibitors.
When compared to best supportive care in patients with advanced clear cell carcinoma, a
first generation Raf kinase and VEGFR inhibitor, Sorafenib, displayed favorable results for
the clinical utility of VEGF pathway-targeted therapy in patients who had previously
received treatment with cytokine based therapy10. When Motzer, et al, compared Sunitinib,
a multitargeted tyrosine kinase inhibitor of vascular endothelial and platelet derived growth
factor receptors, to interferon-alfa as first line therapy in metastatic RCC, progression free
survival was significantly longer in sunitinib (11 months) than in interferon-alfa (5 months)
and, in their final analysis, objective response rate for sunitinib was 47% compared to 12%
for interferon-alfa11, 12. Furthermore, sunitinib displayed a reduced toxicity profile, with
patients reporting less treatment-related fatigue and better quality of life for sunitinib than
for interferon-alfa11. Pazopanib, another VEGFR inhibitor that also inhibits platelet-derived
growth factor receptor and c-Kit, significantly prolonged progression free survival when
compared to placebo in a phase III study in treatment-naïve and cytokine pre-treated patients
with advanced RCC (9.2 vs 4.2 months)13. Investigators also observed a significantly higher
objective response rate of 30% with pazopanib compared to 3% with placebo, with no
clinically important changes in quality of life reported for pazopanib treatment13. These
studies have placed VEGFR directed therapy as a consistently effective treatment option for
a substantial number of patients, even in largely unselected populations of clear cell
histology tumors.
In addition to targeting the VEGF receptor, the humanized anti-VEGF monoclonal antibody,
Bevacizumab, was shown to significantly lengthen progression free survival when combined
with interferon-alfa as compared to interferon-alpha alone as first line treatment in
metastatic renal cell carcinoma9. Therefore, these studies display that VEGF-targeted
therapy provides enhances efficacy over immunotherapy options for advanced renal cell
carcinoma and validates the premise of molecular targets increasing cancer treatment
efficacy.
mTOR directed therapy
Therapeutic targeting of the mammalian target of rapamycin (mTOR) pathway, which
promotes cell proliferation and motility, has also proven effective in the treatment of
advanced RCC14. Despite the fact that the prevalence of mTOR pathway activation remains
to fully be evaluated in RCC, treatment of advanced RCC with temsirolimus, a currently
approved mTOR inhibitor, displays prolonged overall survival compared with interferon as
first line therapy in poor risk patients of all histologic subtypes15. Another mTOR inhibitor,
everolimus, improved progression free survival when compared with placebo in patients
who experienced disease progression while on VEGFR targeted therapy, although the
impact on overall survival is not known16. Therefore, while the exact mechanism of action
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for mTOR therapy in RCC remains unknown, mTOR inhibitors have proven to be an
effective treatment option for patients with advanced disease14.
Clinical features to predict response to targeted therapy
Traditionally, pre-treatment clinical factors have been used to stratify patients to different
risk classifications in metastatic renal cell carcinoma, and these risk assessments have
proved somewhat useful for guiding therapeutic selection using evidence-based medicine
practices. These factors currently include performance status, disease-free interval, number
of metastatic sites, and laboratory values, such as serum corrected calcium, hemoglobin,
lactate dehydrogenase, and platelet and neutrophil counts. These clinical features are applied
in the preferred MSKCC risk stratification model to stratify patients with metastatic RCC
into three different overall survival groups for treatment originally with immunotherapy, and
more recently in selecting VEGFR versus mTOR directed therapies17. Specifically, patients
classified as poor risk should receive temsirolimus, while good and intermediate risk
patients are most effectively treated with sunitinib first line therapy18. As well, host features
independent of the tumor may imply the greater or lesser degrees of drug activity. For
VEGF targeted therapies, hypertension, a side effect caused by the therapy’s mechanism of
action, also serves as a clinical indicator of VEGF signaling inhibition and warrants further
exploration of whether the ambulatory blood pressure can be used to optimize therapy or
track tumor response to VEGF-targeted therapy19.
As expanded understanding of molecular tumor characteristics and more advanced clinical
diagnostics are developed, prolonged progression free survival and enhanced response rates
are being observed. However, despite the advances in treatment of advanced renal cell
carcinoma, the enhanced responses provided by these various targeted therapies remain
modest and leave room for both treatment selection to optimize treatment efficiency and for
therapeutic development. As such, molecular classification schema for advanced RCC also
must evolve to allow for optimal treatment selection for tumors.
Molecular Classification, benefit for use of current therapy
In addition to new therapies, the ability to choose the most effective treatment for individual
tumors will also increase the efficiency of first line therapy for advanced RCC. By
investigating the activated molecular components of a specific tumor, appropriate therapy
attacking those molecules can be utilized, providing a clear rationale for treatment selection.
With the recent proliferation of targeted therapies for RCC, intensive work is underway to
provide molecular biomarkers of response to these therapies, primarily anti-VEGF therapies
and mTOR inhibitors. The various indicator molecules being investigated for these therapies
are selected based on the mechanism of the drug against the RCC tumor biology. Since VHL
mutation is observed in more than 70% of sporadic ccRCC, the exquisite single agent
activity of VEGF-targeted therapies is attributed to loss of the pVHL E3 ubiquitin ligase
complex, resulting in increased HIF-α expression and upregulation of the hypoxia inducible
genes, including VEGF9. As such, molecular indicators that would logically predict
response to VEGF-therapy are VHL mutation status, HIF-α expression level, and VEGF
expression level.
Despite the high prevalence of VHL mutations in RCC, VHL mutation status did not clearly
affect the objective response rate of tumors treated with VEGF-targeted therapies20, 21. In
these studies, VHL mutation status was classified as a change in amino acid sequence, a
truncated protein, or VHL or promoter methylation, and, when analysis included all types of
these VHL mutations, no affect on response rate to anti-VEGF therapies was observed20, 21.
Interestingly, Rini et al observed an increased median TTP in tumors with evidence of VHL
methylation or VHL mutation that was predicted to shift the reading frame compared to
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tumors with no change in VHL (13.3 vs. 7.4 months)20. Upon further classification of VHL
mutation status, Choueiri et al. found that mutations predicted to cause loss of pVHL
function had a significantly increased response rate compared with wild-type VHL (52% vs.
31%), suggesting that further exploration of the specific VHL mutation status may be
warranted21.
The modest effects of VHL mutations on tumor response to VEGF-targeted therapy can be
attributed to many factors. First, the authors of both studies did not fully explore the extent
of loss of heterozygosity (LOH) in the RCC tumor samples. While 85–98% of clear cell
RCC with somatic mutation of VHL also exhibit loss of the other VHL allele, not all tumors
with a VHL mutation necessarily experienced LOH and could possibly retain a normal VHL
allele and, therefore, some functional pVHL22. In addition to further exploring the VHL
mutation status, elucidation of the downstream effects of the mutations in VHL on VEGF
expression remains a complicated task due to both the diverse implications of various
mutations and the complicated nature of tumor biology. Indeed, the effects of VHL
mutations on protein activity remain difficult to classify and even the point mutation R167Q,
recognized to cause ccRCC, pheochromocytoma, and hemangioblastoma in the familial von-
Hippel Lindau syndrome, retains HIF-α ubiquitylation activity in vitro23. In 40% of the
mutations analyzed by Rini et al, only 1 or 2 amino acids were altered, potentially allowing
the pVHL E3 ubiquitin ligase complex to retain some residual activity in these tumors20.
VHL promoter methylation status also could have ambiguous effects on VHL expression,
potentially allowing residual activity of pVHL. Finally, an elevated response rate to VEGF-
targeted therapy could be observed in tumors without VHL mutations if these tumors exhibit
VHL-independent activation of the HIF pathway, allowing the targeted therapy to still act on
increased VEGF expression. Therefore, since VHL mutation status did not precisely
associate with tumor response to VEGF-targeted therapy, downstream molecules more
closely related to VEGF activation should be explored as potential predictors of response to
VEGF-targeted therapy.
Directly downstream of pVHL, HIF-α is the next logical molecule to explore as a potential
biomarker of response to anti-VEGF therapy. In fact, in contrast to VHL mutations,
increased baseline levels of HIF-1α or HIF-2α were associated with an increased objective
response rate of advanced RCC to sunitinib24. Despite the seeming potential of using HIF-α
as predictor of response, many factors contribute to the complexity of HIF-α expression,
complicating its predictive value. First, multiple forms of HIF-α exist, with HIF-1α and
HIF-2α most commonly implicated in the development of RCC, as nicely summarized in a
recent review25. While both HIF-1α and HIF-2α are induced by hypoxia and can be
overexpressed in RCC, they are not functionally redundant, acting in both overlapping and
distinct pathways. Proliferation signatures are preferentially induced by HIF-2α, while
gluconeogenesis and profiles consisted with apoptosis are frequently induced by HIF-1α 25.
In RCC samples, HIF-1α and HIF-2α are also differentially expressed, with HIF-2α
typically being considered more oncogenic than HIF-1α 25. Therefore, when analyzing the
clinical utility of HIF-α as a predictor of response to targeted therapy, the expression of both
HIF-1α and HIF-2α must be measured independently, and, in situations where they are both
expressed, it may be difficult to tease out which isoform is affecting the response. Further
complicating the use of HIF-α in treatment selection, increased expression of HIF-α in RCC
tumor samples can result from HIF-α stabilization either through VHL inactivation or
hypoxia-mediated mechanisms, especially in a highly proliferating tumor environment.
While the mechanism of increased HIF-α expression might not necessarily matter for
VEGF-targeted treatment as long as the result is increased VEGF expression in vivo, the
potential exists that, during nephrectomy, a hypoxic environment ensues, allowing increased
HIF-α expression as an artifact of the surgical procedure and not a feature of the tumor
biology. Since the HIF-α expression levels are typically analyzed by immunohistochemical
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analysis of tumor samples following nephrectomy, hypoxia-induced expression during
surgery could change the HIF-α expression levels from the baseline tumor values in vivo.
However, despite these complexities, HIF-α expression levels have been associated with
distinctions in the staging properties of advanced RCC and, as the directly upstream step to
VEGF over-expression, provide a promising option for further exploration as a predictive
biomarker.
As expected for VEGF-targeted therapy in advanced RCC, VEGF expression levels act as
both a potential pharmacodynamic biomarker and as a very attractive indicator of response
to treatment. The practical application of VEGF expression as a predictive indicator of
response is apparent since increased VEGF expression could make tumors more susceptible
to VEGF inhibition. Furthermore, by directly measuring VEGF levels, you eliminate the
guesswork of the downstream effects of VHL mutation or HIF-α expression on the
therapeutic target. Serum VEGF expression also serves as a very pragmatic measurement
since it is easily attained from patients and can be repetitively measured over the treatment
course.
In determining the utility of VEGF expression as a pharmacodynamic biomarker, two
separate studies found that VEGF serum baseline levels significantly predicted progression
free survival26, 27. Porta et al reported that patients with a baseline serum VEGF level
greater than 707 pg/mL as determined by ELISA (normal range: 0–707 pg/mL) had a
relative risk of 2.14 of disease progression, which proved to be significantly different from
those below this threshold value 26. Similarly, when Rini et al investigated the utility in
measuring different forms of soluble VEGF (VEGF-A and VEGF-C) and soluble VEGF
receptor (sVEGFR)-3, they observed that lower serum baseline levels of sVEGFR-3 and
VEGF-C are associated with longer progression free survival27. However, VEGF-A levels
are not associated with progression free survival27. Moreover, it remains uncertain how the
circulating levels of VEGF relate to the unique biology of an individual tumor.
To investigate the potential use of VEGF expression as a treatment response indicator, Rini
et al. also analyzed the effect of sunitinib on serum VEGF levels. After measuring plasma
VEGF levels on days 1, 14, and 28 of cycle 1 and days 1 and 28 of cycles 2–4, they
observed that sVEGFR-3 and VEGF-C decreased during therapy27. Also, despite no
correlation between baseline levels and progression free survival for VEGF-A, plasma
VEGF-A levels significantly increased during treatment with sunitinib and decreased back
to near-baseline levels by the end of the off-treatment periods 27. The observation that these
VEGF proteins react differently to VEGF-targeted therapy potentially suggest different
regulatory mechanisms and both of the recognized changes should be investigated to
determine if a certain level of change of either protein correlates with different therapeutic
response rates27. One caveat is that these results were potentially complicated by previous
therapy with bevacizumab, which Rini, et al, recognized to affect the changes in VEGF-A
and sVEGFR-3 levels in a time-dependent manner since last bevacizumab exposure27. This
association could potentially alter the observed changes in serum VEGF levels over the
course of treatment and further exploration of VEGF as an indicator of treatment response
should take this effect into account. As such, to evaluate the use of VEGF expression as an
indicator of response to targeted therapies, change in serum VEGF-A and VEGF-C levels
over the treatment course must be further explored, potentially in patients without previous
exposure to VEGF-targeted therapy.
Similar to the VEGF-targeted therapies, potential pharmacodynamic biomarkers for
response to the mTOR inhibitors include important components of the specific signaling
pathway. Upstream of mTOR, growth factors bind and activate a receptor tyrosine kinase in
the cellular membrane, which activates the PI3K/Akt pathway, resulting in increased levels
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of mTOR through inhibition of TSC228. The initial steps of this cascade may be negatively
regulated by PTEN, a frequently mutated tumor suppressor in many cancers. Once mTOR is
activated, downstream molecules, including phospho-S6 and eIF4E, regulate protein
synthesis and cell growth28. Interestingly, mTOR activation in RCC tumors results in
increased HIF-1α expression, which subsequently increases carbonic anhydrase IX
expression28. To elucidate which molecules in this pathway could potentially serve as
treatment indicators, Cho, et al, selected specific components of this pathway to analyze in
RCC tumors, including carbonic anhydrase IX, phospho-Akt, phospho-S6 ribosomal protein,
and PTEN expression levels and VHL mutation status28.
In their small exploratory analysis of 20 tumors from a randomized phase II trial of
temsirolimus treatment, Cho, et al, observed an association between clinical response to
temsirolimus and higher phospho-S6 expression; 11 of 20 tumors were classified as having
high expression28. Clinical response was defined as partial response, minor response, or
stable disease over more than 4 cycles of therapy. Of the 20 tumors, 19 were acceptable for
phospho-Akt expression analysis and investigators also observed a trend towards a positive
association between phospho-Akt expression and a clinical response (p=0.07)28. No
association was detected between objective response or clinical benefit and carbonic
anhydrase IX expression or VHL mutational status. Additionally, despite the
downregulation of PTEN gene expression in 20–30% of renal cell carcinoma and its regard
as a negative prognostic factor for disease-specific survival in advanced disease, no clear
association was seen between clinical response and PTEN expression28.
Despite the small size of this study, the association between clinical response and higher
phospho-S6 expression and the trend towards an association between clinical response and
phospho-Akt expression warrant further exploration. In other studies of the mTOR pathway,
phospho-S6 was observed to be increased in 59% of ccRCC29 and in vitro analysis also
suggests that PI3K/Akt activation may serve as a biomarker of mTOR response30.
Therefore, due to previous supporting evidence and the reported study by Cho, et al, a larger
trial analyzing the association between expression levels and clinical response to
temsirolimus could help determine the utility of phospho-S6 and phospho-Akt expression as
predictive biomarkers of response to mTOR inhibitors.
The investigation of the potential molecular predictors for response to current treatment
options has uncovered many potential biomarkers warranting further investigation in larger
trials. However, it is also important to recognize that the tumor biology of RCC has proven
to be very complex and molecular pathways discussed above are rarely affected in isolation.
Therefore, these biomarkers and pathways must be analyzed together in clinical practice
when optimizing treatment selection since one tumor may have activation of multiple of the
above pathways. Ideally, this analysis could be combined into a classification scheme which
considers the various affected pathways to devise an optimal treatment strategy for an
individual patient, perhaps even utilizing combination therapy of the targeted therapies.
While no such clear molecular classification scheme has proven effective yet, we are
beginning to uncover potentially effective ways of molecularly classifying patients for
therapeutic selection with currently available agents.
Molecular Classification, potential to direct future therapeutic strategy
Conventional histologic classification schemes incorporate broad histological subtypes of
clear cell, papillary, or chromophobe based on both morphological and immunophenotyping
as well as reporting on general histological features such as Fuhrman grade, appearance of
necrosis, and lymphovascular invasion. These features are subjective by definition, and
while they can provide an immediate assessment of tumor tendencies for aggression, many
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tumors display intermediate characteristics which are ineffective in assigning tumor specific
risk of recurrence or death. As we suggested in the introduction, histologically similar
tumors tend to naturally segregate into subtypes based on molecular features. It is logical to
infer, then, that a priori assignments of tumors into molecular subclassifications may provide
a more robust means of stratifying patients for therapeutic benefit. A number of
classification strategies have been developed which display a new way of looking at renal
cell carcinoma and use an expanded global analysis of activated tumor biology to stratify
tumors by similar molecular features. By broadly analyzing activated downstream pathways,
investigators rely less upon the status of a single biomarker and can synthesize molecular
expression data reflecting the net effect of multiple deregulated pathways. Ultimately, such a
strategy may prove to be superior for selecting the optimal targeted approach for distinct
tumor classifications, increasing therapeutic effectiveness by applying them in the correct
population. Additionally, these classifications may shed light on new molecules for targeted
therapy development.
The first classification scheme builds upon the known tumor biology of VHL mutation to
stratify tumors and to investigate the resulting molecular pathways affected by differential
HIF- 1α and HIF-2α expression31. In this analysis, Gordan, et al, stratified tumors based on
their VHL mutation status and HIF-1α and HIF-2α expression patterns and observed three
groups: ccRCCs with intact VHL, pVHL deficient ccRCCs expressing HIF-1α/HIF-2α
(H1H2), and pVHL deficient ccRCCs expressing only HIF-2α (H2). Distinct molecular
pathway activation was observed in an analysis of the different subgroups in which the
numbers of tumors were balanced between subgroups. The subgroup with intact VHL and
the H1H2 subgroup displaying enhanced Akt/mTOR and ERK/MAPK signaling and the H2
subgroup exhibiting increased levels of cMyc activity and Ki-67 overexpression, resulting in
enhanced proliferation and resistance to replication stress31. Survival data was not available
for these tumors. Since such remarkably different pathways are activated in this
classification, it is predicted that subgroups would display varied responses to molecularly
targeted therapies and such responses demand further exploration.
The use of gene expression profiling to classify clear cell RCC tumor subsets has been
explored as a means to identify consistently distinct subclassifications. Several studies have
persistently demonstrated that at least two stable subsets can be identified by hierarchical
clustering, as recently reviewed32. One large study of 177 clear cell tumors examined
differences in gene expression in relation to clinical features, identifying the existence of at
least two subgroups with clear association with survival33. A classification scheme for clear
cell RCC was recently developed to define two stable subsets based on a limited set of gene
features, identified as ccA and ccB 34. This classification schema, characterized through
core molecular differences in the expression pattern using a novel computational strategy of
pattern recognition, also displays independent association with survival when applied to the
set of 177 tumors described above34. ccA tumors, associated with a better prognosis,
overexpress a more pro-angiogenic profile, while ccB tumors are associated with a poorer
prognosis and express a more immature and aggressive molecular phenotype of genes
involved in epithelial to mesenchymal transition and cell cycle regulation34. Since these two
subgroups of ccRCC express such vastly different molecular profiles, it naturally follows
that such differences will result in them responding to differently molecularly targeted
therapies. Therefore, the application of this classification scheme may have clinical utility as
a predictor of response to targeted therapies and, as such, in the selection of optimal therapy.
Furthermore, as these profiles and the core tumor biology driving their differences are more
fully explored, key therapeutic targets for each subtype may be identified; further advancing
targeted therapy for advanced RCC.
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Finally, enhancing our understanding of the root (genetic) causes of kidney cancers is
essential for building robust and rational targeting strategies. The lessons we have learned
from targeted therapy in diseases such as breast and lung cancer have revealed that
identifying and targeting tumor cell specific molecules provides the most effective methods
of combating these cancers with successes measured in long-term survival. This
advancement will depend on exhaustive examination of the genome and epigenome of renal
cell carcinomas through systemic sequencing of the coding regions, copy number analysis,
and genome wide expression arrays. Several recent studies have explored copy number
variation and cancer exome sequencing using current generation technologies in clear cell
RCC35–38. Encouragingly, trends are emerging which will enable future studies to focus on
high impact genetic regions. Specifically, in addition to the loss of 3p well-associated with
VHL loss, consistent losses of 4q, 6q, 8p, 9p and 14 q and gains of 1q, 5q, and 7 have been
observed (Table 1). One group utilizing these methods to provide deep sequencing of over
3,000 known cancer-associated genes identified inactivating mutations in two genes that
encode histone modification enzymes, SETD2 and JARID1C35. The presence of mutations
in histone modification enzymes could potentially seriously alter the gene expression in such
tumor samples due to the importance of histone function in DNA condensation, which
prevents transcription. In this analysis, they also saw NF2 mutations in tumors with intact
VHL and the involvement of other “probable cancer genes”35. The results of this study
highlight the importance of broadening our exploration of RCC samples to genome-wide
approaches since the mutations in histone modification enzymes would not have been found
in a simple screen of molecules involved in the typical RCC pathogenesis pathways.
A second study that used genome-wide approaches to explore the molecular classification of
ccRCC analyzed genome-wide changes of copy number variations and gene expression
profiles in both VHL-disease associated and sporadic ccRCC tumors36. In their results for
copy number variation, the group observed 14 areas of nonrandom copy-number change,
with equal incidence of deletion and amplification. When determining the relevant genes in
these peaks, Beroukhim, et al, identified VHL, CDKN2A, and CDKN2B as potential genes
in two of the deletion peaks and MYC as the only gene in one of the amplification peaks36.
For these and the remaining peaks, other candidate oncogenes were identified based on the
peak location and genes known to be involved in tumorigenesis36.
This study also used the genomic profiles to classify ccRCC and found that sporadic tumors
without biallelic VHL inactivation segregated into a group similar to tumors with biallelic
VHL inactivation and a group very distinct from the majority of ccRCC. The presence of
tumors with intact VHL, but a similar genomic profile to tumors with biallelic VHL
inactivation potentially suggests a VHL independent activation of that pathway, which could
potentially explain the results seen in the previously discussed study regarding VHL
mutation status as a predictor for response to VEGF-targeted therapy. Interestingly, VHL
disease-associated tumors were more similar to a subgroup of sporadic tumors, except very
homogeneous to each other within that subgroup36. Once again, the merits of genome-wide
approaches to the molecular pathogenesis of RCC are illustrated in this study and require
further inquiry to truly advance the understanding and treatment of RCC.
Conclusions
Advances in targeted therapies for advanced renal cell carcinoma over the past decade are
evident in the number of currently approved therapies and those under development. Such
targeted therapies confer advantages in treatment, including decreased adverse events
compared with immunotherapy and the potential for a more effective therapeutic response.
However, despite the recent progress in developing targeted therapies and their utility,
physicians are still limited in their ability to truly optimize treatment selection for patients
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due to the lack of effective molecular classification of tumors. While exhaustive research is
currently being explored for molecular classification based on currently available targeted
therapies and known molecular pathways, molecules identified by this approach still
demand further validation as pharmacodynamic biomarkers. Molecular classification
schemes also may provide great clinical advantages for treatment strategies since they
typically analyze underlying biology of RCC. Finally, despite clear association with
mutation in VHL and associated pathways, RCC is genetically heterogeneous and requires
genome-wide exploration to fully ambush the tumor from all possible targets. As such,
broadening the knowledge of molecular pathways important in the pathogenesis of RCC will
allow further classification of tumor subtypes and choice of optimal first line therapy for
individual patients.
Future Directions
Further development of targeted therapies both for currently elucidated molecular pathways
involved in the pathogenesis of RCC should continue to allow advances in the clinical
response to such therapies. Furthermore, new studies identifying highly associated genetic or
molecular features should be considered to guide therapeutic development and biology-
stratified clinical trial design. This recognition of other relevant targets and targeting them
will effectively enhance drug activity and effectiveness. For both current and future
molecularly targeted therapies, classifying patients into molecular risk groups will enable
appropriate use of drug treatment to ensure that the most effective therapy gets to the
patients with the greatest likelihood to respond. Finally, enhanced understanding of the
genetic, epigenetic, and molecular features which drive kidney cancer growth and
progression is needed for continued advances in therapeutic development and optimization.
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Table 1
Genomic approaches to understanding clear cell RCC.
Study Genomic strategy Regional deletion Regional Gain Genes Identified
Dalgliesh, et al. 2010 SNP array 6.0 (Affymetrix)
PCR based exon resequencing


















Classical Cytogenetics  3p24.3-p25.3
6q23.1-qter
14q
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